WebSep 19, 2024 · The FlowTriever system is 510 (k)-cleared by FDA and CE marked for the non-surgical removal of clot from peripheral blood vessels, including for the use in the treatment of pulmonary embolism and... WebFeb 9, 2024 · The Inari FlowTriever system allows proceduralists to perform a percutaneous, mechanical thrombectomy of this clot burden without thrombolytics. ... The 2024 multicenter FLARE trial looked at 106 patients …
Inari Medical Announces Randomized Controlled Trial Evaluating …
WebOct 18, 2024 · October 18, 2024—Inari Medical, Inc. announced planned enrollment of the PEERLESS randomized controlled trial (RCT) comparing the clinical outcomes of patients with intermediate-high risk pulmonary embolism (PE) treated with the company’s FlowTriever system versus catheter-directed thrombolysis (CDT). WebMar 6, 2024 · IRVINE, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company with a mission to treat and transform the lives of patients suffering... dick blick royal oak
A Prospective, Single-Arm, Multicenter Trial of Catheter-Directed
WebApr 13, 2024 · April 13, 2024 - 4:01 pm. IRVINE, Calif., April 13, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that it will release its first quarter 2024 financial results on Wednesday, … WebAug 30, 2024 · August 30, 2024—Inari Medical, Inc. announced the planned enrollment of the DEFIANCE randomized controlled trial (RCT). The trial will compare clinical outcomes of patients with iliofemoral deep vein thrombosis (DVT) treated with the company’s ClotTriever system versus treatment with anticoagulation only. WebOct 18, 2024 · IRVINE, Calif., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, announced planned enrollment of the PEERLESS trial. dick blick seattle wa